DEL-1 and Thromboxane A2 in Diabetic Nephropathy Patients
ConditionNephropathy, Diabetic
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-70
SponsorAswan University
About this trial
Diabetic nephropathy is one of the most common microvascular complications of diabetes mellitus and a leading cause of chronic kidney disease. Inflammation and platelet activation are believed to play a significant role in its pathogenesis and progression.
Developmental endothelial locus-1 (DEL-1) is an anti-inflammatory protein that regulates leukocyte adhesion and endothelial function, while thromboxane A2 is a marker of platelet activation and contributes to vascular dysfunction.
This study aims to evaluate serum levels of DEL-1 and thromboxane A2, and their relationship with platelet count in patients with diabetic nephropathy. Additionally, the study investigates the correlation between these biomarkers and disease severity.
This observational cross-sectional study will be conducted on 80 participants, including patients with diabetic nephropathy and healthy controls, to explore the potential role of these biomarkers in disease progression and their possible use as diagnostic or prognostic indicators.
Eligibility criteria
Qualifiers
Adult patients aged between 18 and 70 years.
Patients diagnosed with diabetic nephropathy based on clinical and laboratory findings.
Patients undergoing evaluation or follow-up for diabetic kidney disease.
Ability and willingness to provide informed consent.
Disqualifiers
- Patients with known hepatic disease.
Patients with significant cardiovascular disease.
Patients with malignancy.
Patients who have undergone recent surgery.
Trial design
Treatments tested in this trial
- No intervention
Treatment groups
80 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov